Monday, January 30, 2012

Scattering Tacks In The Road

I might be the only one who finds the irony in this, but, at long last, we have a rapid assay to estimate the activity of the new oral direct thrombin inhibitor, dabigatran.

Just to recap, with coumadin, we can measure PT/INR; for heparin, PTT; and for enoxaparin and its brood, (less rapidly) Factor Xa levels.

Now, we have the HEMOCLOT test.

Created and marketed by Boehringer Ingelheim, the manufacturers of dabigatran. (Edit: sorry!  This is not manufactured by Boehringer - they only published this study.  Boehringer is, however, working on a FAB antibody to dabigitran to use as an antidote, however.)

It's a beautiful piece of business to put a dangerous medication on the market, and then sell the only practical means of monitoring levels.

"Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran."
http://www.ncbi.nlm.nih.gov/pubmed/22227958

3 comments:

  1. I typically find myself agreeing with your analysis of the literature. However, I will take issue with your statement: "I might be the only one who finds the irony in this..."

    Since irony usually results when "actions taken have an effect exactly opposite from what was intended," I would submit that this situation is, actually, not very ironic. It was tragically predictable, as well as emblematic of the medical/marketing industry.

    Now, if the wide-spread use of the assay reveals that the thrombin inhibition is actually just as unpredictable and erratic as INRs are with coumadin, that will be ironic indeed.

    ReplyDelete
  2. Ha! Well. I should edit it to say "I hope everyone finds this tragically predictable" precisely as you say - because, yes, I'm probably preaching to the choir by this point.

    ReplyDelete
  3. Boerhinger is planning on releasing an antidabigatran Fab soon, too... Not just tacks on the road but tire patch kits

    ReplyDelete

Comments on posts > 10 days old will be moderated; blame spammers.